gimli

AMBALALSA stock AI analysis

AMBALALSA Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers

AMBALAL SARABHAI ENT L is a small-cap stock in Healthcare. This Gimli page shows the latest available AMBALALSA price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.

Analyze with AI Open interactive AMBALALSA stock page

Price

₹39.97

1W return

-3.78%

1M return

-16.05%

3M return

+24.32%

6M return

n/a

1Y return

n/a

Market cap

₹n/a

n/a

ROE

+11.54%

ROCE

+11.13%

RSI

44.32

Turnover

₹0.34 cr

Why it can matter in screens

Momentum: AMBALALSA is above 50DMA, below 200DMA; RSI is 44.32.
Returns: 1D -3.17%, 1W -3.78%, 1M -16.05%, 3M +24.32%, 1Y n/a.
Trend levels: 52W high ₹49.98, 52W low ₹30.15, off high -20.03%.
Liquidity: latest turnover is ₹0.34 cr; volume vs 20D is +1.78%.
Valuation/profitability: PE n/a, PB n/a, ROE +11.54%, ROCE +11.13%.
Growth: 3Y sales CAGR +6.04%, 3Y profit CAGR +15.84%.

Quick Answers

What is the latest AMBALALSA stock price?

The latest stored price for AMBALALSA is Rs 39.97 as of 2026-09-18.

Is AMBALALSA above its 50DMA and 200DMA?

AMBALALSA is above 50DMA, below 200DMA. The latest 50DMA is 39.69 and the latest 200DMA is n/a.

What are AMBALALSA PE, ROE and ROCE?

AMBALALSA has PE n/a, ROE +11.54%, and ROCE +11.13% in Gimli's latest available snapshot.

How has AMBALALSA performed recently?

AMBALALSA has returned -16.05% over 1 month, +24.32% over 3 months, and n/a over 12 months in the latest stored data.

Is this stock page investment advice?

No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.

Financials and Ownership

Quarterly income statement

Period	Revenue	EBITDA	PAT	EPS
2026-03-31	65.49 cr	8.72 cr	6.50 cr	0.85
2025-12-31	52.00 cr	6.02 cr	3.06 cr	0.40
2025-09-30	44.45 cr	1.98 cr	-0.56 cr	-0.07
2025-06-30	40.34 cr	9.82 cr	8.22 cr	1.07
2025-03-31	64.81 cr	-0.07 cr	-0.27 cr	-0.03
2024-12-31	49.98 cr	5.06 cr	n/a	nan
2024-09-30	n/a	n/a	n/a	0.34

Annual income statement

Year	Revenue	EBITDA	PAT	EPS
2026-03-31	202.27 cr	26.54 cr	17.80 cr	2.32
2025-03-31	196.19 cr	13.11 cr	4.93 cr	0.64
2024-03-31	172.94 cr	15.92 cr	5.68 cr	0.74
2023-03-31	169.63 cr	20.31 cr	11.45 cr	1.49
2022-03-31	39.66 cr	3.89 cr	2.96 cr	6.16

Balance sheet

Period	Assets	Cash	Debt	Equity
2026-03-31	281.13 cr	6.19 cr	56.53 cr	158.36 cr
2025-03-31	270.04 cr	4.89 cr	50.89 cr	139.98 cr
2024-03-31	249.52 cr	10.75 cr	46.11 cr	136.42 cr
2023-03-31	245.74 cr	10.13 cr	45.20 cr	130.93 cr

Cash flow

Period	OCF	FCF	Cash change
2026-03-31	13.40 cr	7.34 cr	n/a
2025-03-31	-17.62 cr	-20.34 cr	n/a
2024-03-31	8.89 cr	5.98 cr	n/a
2023-03-31	5.72 cr	-14.94 cr	n/a
2022-03-31	n/a	n/a	n/a

Shareholding Trend

No recent data available.

Industry Peers

Symbol	Name	Mcap	PE	ROE	1Y
SUNPHARMA	SUN PHARMACEUTICAL IND L	440,829.82 cr	36.388220	+15.50%	+11.45%
DIVISLAB	DIVI S LABORATORIES LTD	248,876.81 cr	85.407280	+18.37%	+53.39%
TORNTPHARM	TORRENT PHARMACEUTICALS L	163,807.57 cr	75.106636	+17.33%	+35.67%
APOLLOHOSP	APOLLO HOSPITALS ENTER. L	128,608.22 cr	65.670049	+21.03%	+13.94%
ZYDUSLIFE	ZYDUS LIFESCIENCES LTD	116,723.14 cr	26.011308	+16.04%	+10.70%
CIPLA	CIPLA LTD	112,647.78 cr	33.401961	+10.25%	-11.64%
LAURUSLABS	LAURUS LABS LIMITED	105,487.98 cr	96.587446	+21.77%	+111.64%
MAXHEALTH	MAX HEALTHCARE INS LTD	102,122.47 cr	70.799892	+14.33%	-10.58%

Try these prompts

Analyze AMBALAL SARABHAI ENT L with valuation, momentum and industry peers
Compare AMBALALSA with other Healthcare stocks
Show small-cap stocks in Healthcare above 50DMA with positive 1M return
Find Healthcare stocks with improving momentum and reasonable valuation

Related screen ideas

Data snapshot: 2026-09-18. Not investment advice.